SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-002568
Filing Date
2019-02-14
Accepted
2019-02-14 16:20:22
Documents
60
Period of Report
2018-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q rasp-20181231.htm   iXBRL 10-Q 821774
7 EXHIBITS 31.1 ex311_1.htm EX-31.1 16149
8 EXHIBITS 31.2 ex312_2.htm EX-31.2 11903
9 EXHIBITS 32.1 ex321_3.htm EX-32.1 4764
10 EXHIBITS 32.2 ex322_4.htm EX-32.2 4295
11 EXHIBITS 10.1 ex101_5.htm EX-10.1 148813
  Complete submission text file 0001213900-19-002568.txt   5496464

Data Files

Seq Description Document Type Size
2 DEFINITION rasp-20181231_def.xml EX-101.DEF 256482
3 PRESENTATION rasp-20181231_pre.xml EX-101.PRE 423321
4 CALCULATION rasp-20181231_cal.xml EX-101.CAL 38490
5 LABEL rasp-20181231_lab.xml EX-101.LAB 876261
6 SCHEMA rasp-20181231.xsd EX-101.SCH 53400
12 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20181231_htm.xml XML 698063
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 19606676
SIC: 2834 Pharmaceutical Preparations